BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 11042688)

  • 1. Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells.
    Morgan SE; Kim R; Wang PC; Bhat UG; Kusumoto H; Lu T; Beck WT
    Oncogene; 2000 Oct; 19(43):5010-9. PubMed ID: 11042688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA-binding activity, and formation of Jun/Fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26.
    Kim R; Beck WT
    Cancer Res; 1994 Sep; 54(18):4958-66. PubMed ID: 8069863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines.
    Goldwasser F; Bae I; Fornace AJ; Pommier Y
    Oncol Res; 1996; 8(7-8):317-23. PubMed ID: 8938795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of p53 target gene expression by cisplatin-induced extracellular signal-regulated kinase.
    DeHaan RD; Yazlovitskaya EM; Persons DL
    Cancer Chemother Pharmacol; 2001 Nov; 48(5):383-8. PubMed ID: 11761456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An abnormality in the p53 pathway following gamma-irradiation in many wild-type p53 human melanoma lines.
    Bae I; Smith ML; Sheikh MS; Zhan Q; Scudiero DA; Friend SH; O'Connor PM; Fornace AJ
    Cancer Res; 1996 Feb; 56(4):840-7. PubMed ID: 8631022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines.
    Chen M; Beck WT
    Oncol Res; 1995; 7(2):103-11. PubMed ID: 7579726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationships between G1 arrest and stability of the p53 and p21Cip1/Waf1 proteins following gamma-irradiation of human lymphoma cells.
    Bae I; Fan S; Bhatia K; Kohn KW; Fornace AJ; O'Connor PM
    Cancer Res; 1995 Jun; 55(11):2387-93. PubMed ID: 7757991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines.
    Keshelava N; Zuo JJ; Chen P; Waidyaratne SN; Luna MC; Gomer CJ; Triche TJ; Reynolds CP
    Cancer Res; 2001 Aug; 61(16):6185-93. PubMed ID: 11507071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.
    O'Connor PM; Jackman J; Bae I; Myers TG; Fan S; Mutoh M; Scudiero DA; Monks A; Sausville EA; Weinstein JN; Friend S; Fornace AJ; Kohn KW
    Cancer Res; 1997 Oct; 57(19):4285-300. PubMed ID: 9331090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenovirus-mediated transfer of wild-type p53 gene sensitizes TNF resistant MCF7 derivatives to the cytotoxic effect of this cytokine: relationship with c-myc and Rb.
    Ameyar M; Shatrov V; Bouquet C; Capoulade C; Cai Z; Stancou R; Badie C; Haddada H; Chouaib S
    Oncogene; 1999 Sep; 18(39):5464-72. PubMed ID: 10498900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the chemosensitivity of head and neck cancer cells based on the diverse function of mutated-p53.
    Shinagawa Y; Kawamata H; Omotehara F; Nakashiro K; Hoque MO; Furihata T; Horiuchi H; Imai Y; Fujimori T; Fujibayashi T
    Int J Oncol; 2003 Feb; 22(2):383-9. PubMed ID: 12527938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line.
    Cinti C; Claudio PP; Luca AD; Cuccurese M; Howard CM; D'Esposito M; Paggi MG; Sala DL; Azzoni L; Halazonetis TD; Giordano A; Maraldi NM
    Oncogene; 2000 Oct; 19(44):5098-105. PubMed ID: 11042698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme.
    Chen M; Beck WT
    Cancer Res; 1993 Dec; 53(24):5946-53. PubMed ID: 8261408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity.
    Piovesan B; Pennell N; Berinstein NL
    Oncogene; 1998 Nov; 17(18):2339-50. PubMed ID: 9811465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
    Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the GADD45 response to ionizing radiation in WI-L2-NS cells, a p53 mutant cell line.
    Carrier F; Bae I; Smith ML; Ayers DM; Fornace AJ
    Mutat Res; 1996 Jun; 352(1-2):79-86. PubMed ID: 8676920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells.
    Wolverton JS; Danks MK; Schmidt CA; Beck WT
    Cancer Res; 1989 May; 49(9):2422-6. PubMed ID: 2539902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo evidence for binding of p53 to consensus binding sites in the p21 and GADD45 genes in response to ionizing radiation.
    Chin PL; Momand J; Pfeifer GP
    Oncogene; 1997 Jul; 15(1):87-99. PubMed ID: 9233781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytosine arabinoside (ara-C) resistance confers cross-resistance or collateral sensitivity to other classes of anti-leukemic drugs.
    Martin-Aragon S; Mukherjee SK; Taylor BJ; Ivy SP; Fu CH; Ardi VC; Avramis VI
    Anticancer Res; 2000; 20(1A):139-50. PubMed ID: 10769646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.
    Mujoo K; Watanabe M; Nakamura J; Khokhar AR; Siddik ZH
    J Cancer Res Clin Oncol; 2003 Dec; 129(12):709-18. PubMed ID: 14513366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.